Holen Sie sich die Stockscreener-App
67.91
0.34%
-0.23
Handel nachbörslich:
68.82
0.91
+1.34%
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
Insights Ahead: BridgeBio Pharma's Quarterly Earnings - Benzinga
BridgeBio to Participate in March Investor Conferences - The Manila Times
Biotech BridgeBio plans three March investor conference chats - Stock Titan
Blue Owl, Genuine Parts, And Okta Are Among Top 10 Large Cap Losers Last Week (Feb. 16-Feb. 20): Are the Others in Your Portfolio?BridgeBio Pharma (NASDAQ:BBIO), BorgWarner (NYSE:BWA), Expedia Group (NASDAQ:EXPE), Flutter Entertainment ( - Benzinga
BridgeBio Pharma, Inc. $BBIO Shares Sold by HighTower Advisors LLC - MarketBeat
BridgeBio Pharma Inc (BBIO) Stock Price, Quote, News & History - Benzinga
BridgeBio Pharma Inc expected to post a loss of 74 cents a shareEarnings Preview - TradingView
BridgeBio (BBIO) Shares Dip After UBS Summit Withdrawal - GuruFocus
16,893 Shares in BridgeBio Pharma, Inc. $BBIO Purchased by L & S Advisors Inc - MarketBeat
Skandinaviska Enskilda Banken AB publ Has $7.74 Million Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Randal Scott Sells 10,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock - Defense World
Bank of America Securities Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
Oppenheimer & Co. Inc. Takes $407,000 Position in BridgeBio Pharma, Inc. $BBIO - Defense World
HC Wainwright Boosts Earnings Estimates for BridgeBio Pharma - MarketBeat
NEOS Investment Management LLC Has $5.02 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) CAO Maricel Apuli Sells 510 Shares - MarketBeat
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CFO Sells 13,600 Shares of Stock - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Director Randal Scott Sells 10,000 Shares - MarketBeat
BridgeBio Pharma director Scott sells $754k in BBIO stock - Investing.com
BridgeBio Pharma CAO Apuli sells $37898 in BBIO stock By Investing.com - Investing.com Canada
BridgeBio Pharma CAO Apuli sells $37898 in BBIO stock - Investing.com
BridgeBio Pharma (BBIO) Valuation Check After Strong Phase 3 PROPEL 3 Results In Achondroplasia - Yahoo Finance
BridgeBio earnings up next: Can pipeline wins fuel growth? By Investing.com - Investing.com Canada
BridgeBio earnings up next: Can pipeline wins fuel growth? - Investing.com Australia
BridgeBio Pharma, Inc. $BBIO Shares Sold by Readystate Asset Management LP - MarketBeat
Cibc World Market Inc. Takes Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BoFA Notes BridgeBio Pharma, Inc. (BBIO)’s Upcoming Q4 Earnings May Have Limited Market Impact - Insider Monkey
BridgeBio plans $550M convertible notes offering due 2033 - MSN
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $100.00 - MarketBeat
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET - The Manila Times
BridgeBio Pharma, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - Quiver Quantitative
BBIO: Today's Analyst Rating Insights by HC Wainwright & Co. | B - GuruFocus
BBIO stock surges 17% pre-market today – what’s fueling the rally? - MSN
Is BridgeBio Pharma Inc. still a buy after recent gainsJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - mfd.ru
Published on: 2026-02-15 17:09:25 - mfd.ru
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), American Well (AMWL) and BridgeBio Pharma (BBIO) - The Globe and Mail
Is BridgeBio Pharma Inc. a stock for growth or value investorsJuly 2025 Price Swings & Stepwise Trade Signal Guides - mfd.ru
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia - Yahoo Finance
BridgeBio Pharma, DoorDash, Nvidia, Rio Tinto: What brokers said this week - Proactive financial news
Is BridgeBio Pharma Inc. a speculative investment2025 Top Decliners & AI Driven Stock Movement Reports - mfd.ru
BridgeBio Pharma (NASDAQ:BBIO) Given New $83.00 Price Target at Oppenheimer - MarketBeat
BBIO: Oppenheimer Raises Price Target for BridgeBio Pharma | BBI - GuruFocus
BridgeBio's Impressive Phase 3 Infigratinib Data Adds Competitive Pressure to BioMarin's Voxzogo - Morningstar
Oppenheimer Adjusts BridgeBio Pharma Price Target to $83 From $81, Maintains Outperform Rating - marketscreener.com
BBIO: Wells Fargo Raises Price Target to $98 While Maintaining 'Overweight' Rating | BBIO Stock News - GuruFocus
Wells Fargo & Company Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
BridgeBio looks to challenge BioMarin in dwarfism market on Phase III win - Clinical Trials Arena
BridgeBio Pharma stock hits all-time high at 84.51 USD By Investing.com - Investing.com Canada
BBIO Stock Surges 19% With A 5-day Spree On Positive Phase 3 Trial Data - Trefis
Jefferies Maintains Buy on BBIO BridgeBio Pharma, Inc. Feb 2026 - Meyka
Allspring Growth Fund Q4 2025 Fund Performers And Detractors - Seeking Alpha
2.25%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):